Abilita Therapeutics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 13

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 4

Abilita Therapeutics General Information

Description

Developer of oncological drugs designed to target membrane proteins. The company leverages technology-directed evolution to identify target variants (EMPs) that can overcome the challenges, yet maintain the relevant protein structure, enabling clinicians to have access to tool receptors for antibody discovery and technical service through the generation of enabled membrane proteins.

Contact Information

Website
abilitatx.com
Formerly Known As
Abilita Bio
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 6888 Nancy Ridge Drive
  • San Diego, CA 92121
  • United States
+1 (858) 000-0000

Abilita Therapeutics Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Abilita Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Accelerator/Incubator 00.00 Completed Pre-Clinical Trials
5. Seed Round 21-Feb-2023 00.00 00.00 000.00 Completed Pre-Clinical Trials
4. Grant 15-Sep-2021 00.000 Completed Product Development
3. Grant 20-Sep-2016 00000 Completed Product Development
2. Accelerator/Incubator 01-Jan-2015 Completed Product Development
1. Angel (individual) 01-Jan-2015 Completed Product Development
To view Abilita Therapeutics’s complete valuation and funding history, request access »

Abilita Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed-3 000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Seed-2 000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Seed-1 177,788 $0.000010 8% $1.49 $1.49 1x $1.49 2.29%
Seed 2,114,462 $0.000010 8% $3.55 $3.55 1x $3.55 19.76%
To view Abilita Therapeutics’s complete cap table history, request access »

Abilita Therapeutics Patents

Abilita Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-10845367-B2 Modified multispanning membrane polypeptides and methods of use thereof to screen therapeutic agents Active 04-May-2016 0000000000 00
US-20190137496-A1 Methods and platform for preparing multispanning membrane proteins Active 04-May-2016 0000000000
EP-3452516-A1 Methods and platform for preparing multispanning membrane proteins Pending 04-May-2016 0000000000
EP-3452516-A4 Methods and platform for preparing multispanning membrane proteins Pending 04-May-2016 0000000000 0
AU-2017259821-A1 Methods and platform for preparing multispanning membrane proteins Pending 04-May-2016 G01N33/577
To view Abilita Therapeutics’s complete patent history, request access »

Abilita Therapeutics Executive Team (7)

Name Title Board Seat Contact Info
Mauro Mileni Ph.D Founder, Chief Executive Officer & Board Member
James Schmidt Chief Financial Officer
Joel Edwards Chief Business Officer
Charlie Rodi Ph.D Executive Advisor
You’re viewing 4 of 7 executive team members. Get the full list »

Abilita Therapeutics Board Members (3)

Name Representing Role Since
Daniel Bradbury Self Board Member 000 0000
Mauro Mileni Ph.D Abilita Therapeutics Founder, Chief Executive Officer & Board Member 000 0000
Michael Goguen Two Bear Capital Board Member 000 0000
To view Abilita Therapeutics’s complete board members history, request access »

Abilita Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Abilita Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Two Bear Capital Venture Capital Minority 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
Johnson & Johnson Innovation - JLABS Accelerator/Incubator 000 0000 000000 0
CONNECT (Accelerator) Accelerator/Incubator 000 0000 000000 0
To view Abilita Therapeutics’s complete investors history, request access »

Abilita Therapeutics FAQs

  • When was Abilita Therapeutics founded?

    Abilita Therapeutics was founded in 2014.

  • Who is the founder of Abilita Therapeutics?

    Mauro Mileni Ph.D is the founder of Abilita Therapeutics.

  • Who is the CEO of Abilita Therapeutics?

    Mauro Mileni Ph.D is the CEO of Abilita Therapeutics.

  • Where is Abilita Therapeutics headquartered?

    Abilita Therapeutics is headquartered in San Diego, CA.

  • What is the size of Abilita Therapeutics?

    Abilita Therapeutics has 13 total employees.

  • What industry is Abilita Therapeutics in?

    Abilita Therapeutics’s primary industry is Drug Discovery.

  • Is Abilita Therapeutics a private or public company?

    Abilita Therapeutics is a Private company.

  • What is Abilita Therapeutics’s current revenue?

    The current revenue for Abilita Therapeutics is 000000.

  • How much funding has Abilita Therapeutics raised over time?

    Abilita Therapeutics has raised $7.5M.

  • Who are Abilita Therapeutics’s investors?

    Two Bear Capital, U.S. Department of Health and Human Services, Johnson & Johnson Innovation - JLABS, and CONNECT (Accelerator) have invested in Abilita Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »